Mammalian cells produce energy by oxidative phosphorylation under aerobic conditions. However, in the 1920s, Otto Warburg reported the so-called "Warburg effect" in which cancer cells produce ATP that is biased toward glycolysis rather than mitochondrial oxidative phosphorylation not only in anaerobic environment but also in aerobic environment. Glucose is converted into lactate without going into mitochondria after being metabolized in glycolysis. Compared with oxidative phosphorylation, the glycolysis has a faster ATP production rate but it is very inefficient, resulting in cancer cells consuming a large amount of glucose. Increased glucose metabolism has become a biomarker for cancer cells and has led to the development of positron emission tomography with fluorodeoxyglucose. Till date, the Warburg effect has been an inefficient system for cancer cells with regard to efficient energy production, but since the consumption of oxygen can be suppressed as the tumor grows in mass, it is thought that the Warburg effect is advantageous in this situation wherein the tumor can increase despite the lack of vessels. In addition, an increased lactate by the glycolysis causes acidosis in the microenvironment of tissues, which is thought to damage the surrounding normal tissues and favor the invasion and metastasis of cancer. Thus, Warburg effect is one of the key mechanisms for cancer development and will be the next promising target. In this review, we introduce key players that can be targeted in the Warburg effect and outline the prospects of treatment, targeting the Warburg effect in gynecological cancer.
Introduction
The advent of high-throughput DNA sequencing has highlighted that metabolic changes in cancer are uniform, as is the case with glycolysis acceleration, while it has revealed the diverse and complex nature of cancer-related genetic mutations. 1 From one glucose molecule, each cell produces several ATP molecules: two through the glycolysis, two through the tricarboxylic acid (TCA) cycle and 34 through the electron transport chain. In cancer cells, glycolysis is typically accelerated; a large amount of glucose is metabolized through the glycolysis and then converted into lactate, without entering the mitochondria to undergo oxidative phosphorylation. This phenomenon can be observed even under aerobic conditions and is designated as the Warburg effect (Fig. 1) . [2] [3] [4] In recent years, research on cancer metabolism has regained center stage and revealed that cancer cells use the glycolysis to produce precursors such as those of nucleic acids, proteins and lipids. 5 Because cancer cells require large amounts of energy to survive, understanding energy metabolism based on the Warburg effect is crucial to develop effective anticancer treatments, targeting the energy production circuitry of cancer cells. In this review, we introduced recent findings on gynecologic cancers and the Warburg effect based on available research results.
Key Players in the Warburg Effect in Cancer
Pyruvate kinase M
In cancer cells, metabolic adjustment was thought to be caused by genetic or epigenetic modifications, involving increased expression of the glucose transporter (GLUT)1, 3, which takes glucose into the cells, and the regulatory factors of glycolysis, such as hexokinase 2 and 6-phosphofructo-1-kinase. During glycolysis, the conversion from phosphoenolpyruvate into pyruvate is an irreversible reaction catalyzed by pyruvate kinase muscle (PKM). PKM has two isoforms, PKM1 and PKM2, which result from selective splicing. While PKM1 forms the constitutively active tetramer, PKM2 activation is conditional and requires an allosteric factor. 6, 7 It has previously been observed that replacing the expressed isoform with PKM1 in a human cell line expressing PKM2 reduces the Warburg effect. Moreover, cell lines expressing PKM2 grow faster under hypoxia and tumor growth with a xenograft model than cell lines expressing PKM1. 8 While PKM1 is expressed in normal cells, most cancer cells express PKM2. This switch in the PKM isoform plays an important role in the Warburg effect. Another important enzyme contributing to the Warburg effect is lactate dehydrogenase A (LDHA), which converts pyruvate into lactate. LDHA expression increases in many cancer cells, and its absence or inhibition slows tumor growth and facilitates the inflow of glucose into TCA cycle.
9,10
Hypoxia-inducible factor-1
Both acceleration of glycolysis and suppression of aerobic respiration in cancer cells are controlled by the transcription factor hypoxia-inducible factor-1 (HIF1). Although HIF1 was originally identified as a factor that is activated under hypoxia conditions and induces hematogenesis, 11 it was later shown to contribute to neoangiogenesis and glycolysis, being currently recognized as a master regulator activating hypoxia responses. When cancer cells grow to form a tumor mass, the concentration of oxygen at the center drops, placing cells under hypoxia conditions and activating HIF1. 12 HIF1 facilitates oxygen delivery into the tumor through inducing the expression of factors that create blood vessels as well as taking in glucose and producing energy through glycolysis, thereby creating an environment where growth is possible with minimal oxygen consumption. Adjustment of the inner tumor environment by HIF1 is induced by hypoxia or oncogenes such as Ras, Src and PI3K, facilitating the expression of glycolysis enzymes, LDHA and pyruvate dehydrogenase kinase 1 (PDK1). In addition, HIF1 lowers mitochondrial biosynthesis by indirect suppression of the oncogene cMyc, which induces cellular proliferation. If the Warburg effect is an adaptive response of cancer cells to hypoxia conditions, HIF1 plays an important role in the process.
p53
Many types of cancer, including those prevalent in women, present modifications in the tumorsuppressor gene TP53. p53 is activated and arrests cell cycle when DNA is damaged, facilitating DNA damage to control its mutation. It also eliminates cells with mutated DNA by eradicating those that cannot be repaired through apoptosis. 13 In addition to these mechanisms, p53 suppresses oncogenesis by inducing apoptosis and cellular aging to eliminate cells with abnormal growth control. p53 mutations can lead to oncogenesis.
14 p53 is related to cancer metabolism; it controls energy metabolism by reducing glycolysis and increasing mitochondrial respiration through controlling the expression of various genes, including suppression of the expression of GLUT1 and GLUT4 and induction of the expression of TP53-inducible glycolysis and apoptosis regulator (TIGAR). [15] [16] [17] It also induces the expression of SCO2, a control factor for cytochrome c oxidase complex necessary for the mitochondria respiration. The lack of p53 in cells lowers oxygen consumption within the mitochondria via decreased expression of SCO2. 18 It can therefore be considered that cells with p53 dysfunction exhibit low mitochondria respiration and repressed Warburg effect. p53 controls many metabolic pathways, and because energy metabolism is essential for tumor suppression, future cancer treatments may target p53-mediated regulation of the energy metabolism pathway.
Reverse Warburg effect
In recent years, a model known as the reverse Warburg effect has been proposed for several types of cancer, such as breast cancer and prostate cancer (Fig. 2) . This model stipulates that glycolysis acceleration does not occur in cancer cells but in the stromal cells at the periphery. [19] [20] [21] [22] The designation of 'reverse Warburg effect' is due to the cancer cells using the high energy metabolism produced by the Warburg effect in the cancer-associated fibroblasts (CAFs). Reactive oxygen species (ROS) generated in cancer cells affects adjacent microenvironment and CAFs, which results in oxidative stress. Oxidative stress leads to activation of HIF1 and nuclear factor kappalight-chain-enhancer of activated B (NFκB), and loss of stromal Caveolin-1(CAV1) which in turn activates glycolysis and upregulates monocarboxylate transporter (MCT) 4(MCT4). Lactate is released from CAFs and uptaken by cancer cells via MCT1 with upregulation of TP53 induced glycolysis and apoptosis regulator (TIGAR). [23] [24] [25] [26] This catabolite transfer, which induces stromal-cancer metabolic coupling, allows cancer cells to have high mitochondrial oxidative phosphorylation (OXPHOS) and low glycolysis. Taken together, the reverse Warburg effect is newly identified as a novel metabolic phenomenon and will be a promising target for anti-cancer therapies.
Gynecologic Cancers and the Warburg Effect Endometrial cancer
Endometrial cancer is the most frequent form of malignant tumor occurring in women in developed countries. 27 One factor contributing to the increase in prevalence of this disease is the increase in metabolic syndrome, which triggers high estrogen and high insulin conditions. 28 Metformin, a drug expected to become an effective treatment for endometrial cancer, is currently prescribed to treat type-2 diabetes because it suppresses glyconeogenesis in the liver through glucose-6-phosphatase inhibition, thereby lowering blood glucose levels. 29 It also exerts a multifaceted effect on cell energy production and usage, thereby raising the hope that it can be used for reprogramming cancer. 30 In the reverse Warburg effect model, metformin is thought to inhibit cancer cell metabolism by directly interfering with aerobic respiration. This is not contradictory with a previous report indicating that metformin administration to breast cancer cell cultures inhibits CAV1 loss in co-cultured fibroblasts, 21 and a report of increased stromal CAV1 expression in patients with head and neck squamous cell carcinoma who received metformin administration. 31 There is high hope for metformin to be used in the future as anti-tumor treatment targeting the reverse Warburg effect.
Cervical cancer
Cervical cancer is one of the most frequent causes of deaths due to cancer in women worldwide. 32 Its main etiology is thought to be high-risk human papillomavirus (HPV) infections. 33 MicroRNA is known for its significant role in cell proliferation and differentiation, and previous studies have shown its involvement in the diagnosis, prognosis and treatment performance of several human cancers. 34 The study investigating the effects of miRNA on the Warburg effect in cervical cancers found that knocking down E6, a p53-inactivating tumor protein coded by HPV, in the cervical cancer cell lines SiHa and HeLa, results in a lower expression of miR-34a and a weaker Warburg effect. 35 Moreover, silencing LDHA significantly lowered the colony formation and infiltration abilities of SiHa and HeLa cells. Because miR-34a and LDHA directly target p53 and miR-34a, respectively, the E6/p53 signal from HPV makes miR-34a/LDHA unregulated, thus adjusting the Warburg effect and facilitating the expansion and infiltration of the tumor, in cervical cancer. Therefore, miR-34a may become a target for cervical cancer treatments in the future. Metformin also reduces the Warburg effect through inhibiting HIF1 in SiHa cells, and it was found to induce apoptosis by suppressing the expression of c-Myc. 36 Because activation of HIF1 and c-Myc leads to increased expression of glycolysis enzymes, in the future metformin may become a drug for treatment of both endometrial and cervical cancers.
Ovarian cancer
240 000 women are diagnosed with ovarian cancer every year and, with 5-year survival below 45%, it is responsible for 15 000 deaths making it the 7th most common cancer and 8th most common cause of cancer death among women. Therefore, in addition to the standard chemotherapy currently in use, there is an urgent need to develop pharmaceutical treatments based on new targets. We have previously suggested the therapeutic potential of targeting the Warburg effect in ovarian cancer. 37 A previous study using capillary electrophoresis-mass spectrometry to investigate the mechanisms of statins found that addition of statins to ovarian cancer cell lines led to a significant increase in metabolites related to the TCA cycle, such as tryptophan, valine, methionine and phenylalanine. Moreover, a significant decrease in the NADH/NAD+ ratio was observed. NAD is a major coenzyme in the electron transport chain; its oxidized and reduced forms are designated as NAD+ and NADH, respectively. When the TCA cycle is activated, the NADH/NAD+ ratio decreases, since NAD+ is reduced to NADH and then transformed back into NAD+ to produce ATP. Therefore, the results showed that statin administration activates the TCA cycle. Further, addition of statin to cells leads to a significant increase in acetyl-CoA and a significant decrease in lactate. Tumor cells produce energy through aerobic glycolysis rather than oxidative phosphorylation in the mitochondria, which is referred to as the Warburg effect. The results indicated that statin administration avoids the Warburg effect, which is unique to cancer cells, and activates the TCA cycle, shifting the energy production in cancer cells to oxidative phosphorylation. Since statins reduced the development of serous tubal intraepithelial carcinomas in transgenic ovarian cancer model mice and inhibited ovarian tumor growth in the mouse xenograft model, 38 interfering Warburg effect may play an import role in statins anti-tumor effect. 39 Repositioning statin drugs for ovarian cancer may provide a promising strategy to prevent and manage this devastating disease.
Other studies targeting the Warburg effect in ovarian cancer have focused on miR-145, which is thought to suppress the Warburg effect. In ovarian cancer, there is excessive expression of DNA methyltransferase (DNMT)3A and silencing of miR-145. However, a relationship between the two has not been identified from a molecular cytological perspective. In this study, it was found that miR-145 silencing leads to a rise in DNMT3A expression and the overexpression of miR-145 leads to downregulation of DNMT3A; hence, miR-145 and DNMT3A act in a mutually negative feedback. 40 MiR-145 is considered to not only suppress hexokinase 2 (HK2) directly but also lower the expression of PKM2 and LDH indirectly and reduce the consumption of glucose and the production of lactate.
However, DNMT3A increases HK2 and enhances the expression of PKM2; hence, it is thought to facilitate the Warburg effect. However, DNMT3A adjusts HK2 not directly but through miR-145. Exploring the mutually negative feedback between miR-145 and DNMT3A may result in the use of miR-145 and DNMT3A inhibitors as treatments for ovarian cancer. It was also found that 20(S)-Rg3, a bioactive substance present in ginsenoside used for diabetes and arteriosclerosis, exerts anti-Warburg effects in ovarian cancer cells. 41 This is because 20(S)-Rg3 reverts miR-532-3p methylation by DNMT3A, which upregulates miR-532-3p and enhances the inhibitory effects of HK2. Previous studies have found that dicumarol, a coumarin compound and raw anticoagulant material, prevents PDK1 production in ovarian cancer cells, shifting the anaerobic respiration of the glucose metabolism into oxidative phosphorylation. 42 This causes an increase in oxidation and a decrease in the mitochondrial membrane potential, leading to leakage of cytochrome c from the mitochondria, which eventually induces apoptosis. As a result, the surviving ability of cancer cells is hampered and tumor growth is suppressed. PKM2 may also become a future target for ovarian cancer treatment. 43 Shiconin, a component of Lithospermum erythrorhizon, was identified as a natural inhibitor of PKM2 with an IC50 value of 0.3 μM and could be a candidate drug for ovarian cancer. 44 
Conclusion
The Warburg effect is the key mechanism for cancer growth. Therefore, molecules targeting it could help in future cancer treatments. In a time where new drugs such as anti-VEGF humanized monoclonal antibody bevacizumab or poly ADP-ribose polymerase inhibitors and immune checkpoint inhibitors are available, cancer metabolism could become the next candidate for the development of a groundbreaking new drug. Existing drugs have also been reported to influence the Warburg effect, and repositioning of currently existing drugs is also anticipated. Further research is needed in this field to explore such promising advances.
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